Hepatitis B, a viral infectious disease caused by hepatitis B virus (HBV), is a life-threatening disease that leads liver cirrhosis and liver cancer. Because the current treatments for HBV, such as an interferon (IFN) formulation or nucleoside/nucleotide analogues, are not sufficient, the development of a more effective agent for HBV is urgent required.CDM-3008 (
1, 2-(2,4-bis(trifluoromethyl)imidazo[1,2-
a][1,8]naphthyridin-8-yl)-1,3,4-oxadiazole) (RO8191)) is a small molecule with an imidazo[1,2-
a][1,8]naphthyridine scaffold that shows anti-HCV activity with an IFN-like effect. Here, we report that
1 was also effective for HBV, although the solubility and metabolic stability were insufficient for clinical use. Through the structure-activity relationship (SAR), we discovered that CDM-3032 (
11,
N-(piperidine-4-yl)-2,4-bis(trifluoromethyl)imidazo[1,2-
a][1,8]naphthyridine-8-carboxamide hydrochloride) was more soluble than
1 (>30?mg/mL for
11 versus 0.92?mg/mL for
1). In addition, the half-life period of
11 was dramatically improved in both mouse and human hepatic microsomes (T1/2, >120?min versus 58.2?min in mouse, and >120?min versus 34.1?min in human, for
11 and
1, respectively).
相似文献